Gd. Anderson et al., ABSENCE OF BLEEDING COMPLICATIONS IN PATIENTS UNDERGOING CORTICAL SURGERY WHILE RECEIVING VALPROATE TREATMENT, Journal of neurosurgery, 87(2), 1997, pp. 252-256
Valproate (VPA) is associated with a variety of idiosyncratic hematolo
gical effects including thrombocytopenia, inhibition of platelet aggre
gation, and fibrinogen depletion. This has led some investigators to r
ecommend discontinuation of VPA therapy prior to elective surgical pro
cedures. However, administration of VPA therapy is not altered prior t
o surgery at the authors' center and no VPA-associated bleeding compli
cations have been observed. Therefore, a retrospective chart review wa
s conducted to verify the clinical observations in patients who had un
dergone cortical resection while receiving antiepileptic drugs (AEDs).
Baseline, surgical, and postoperative laboratory data were available
for a total of 313 patients, 111 of whom were receiving VPA and 202 of
whom were receiving AEDs without VPA (control patients). Eighty-seven
percent of the patients receiving VPA were also being treated with at
least one other AED. The control group was approx imately equally div
ided between monotherapy (55%) and polytherapy (45%) treatments. Plate
let counts were significantly lower in the control polytherapy (284 +/
- 74 X 10(9)/L) and both VPA groups (279 +/- 113 X 10(9)/L) as compare
d with the control monotherapy group (314 +/- 85 X 10(9)/L). Baseline
fibrinogen levels were significantly lower in the VPA than in the cont
rol groups (223 +/- 91 g/dl vs. 278 +/- 95 g/dl). Both pre- and postop
eratively, the VPA group had lower red blood cells counts, hematocrit,
and hemoglobin levels. There was no significant difference between gr
oups in estimated blood loss during surgery or qualitative wound disch
arge postsurgery. There was only one case of a bleeding complication,
which occurred 14 days postoperatively in a patient receiving carbamaz
epine monotherapy. The results of this study confirm the clinical obse
rvations of an absence of bleeding complications in patients receiving
VPA therapy at the time of surgery, despite differences in laboratory
parameters.